Atovakon/Proguanil Glenmark

Atovakon/Proguanil Glenmark combines Atovaquone and Proguanil Hydrochloride for oral use. This medication is commonly used for malaria prevention and treatment. It is manufactured by Glenmark Arzneimittel Gmbh and is available in the EU market.

Atovakon/Proguanil Glenmark is primarily used for the prevention and treatment of malaria. This combination medication works by interfering with the growth of parasites in the red blood cells of the human body. It is often prescribed for travelers to areas where malaria is prevalent, as well as for those who have been diagnosed with the disease.

Common effects of Atovakon/Proguanil Glenmark may include nausea, vomiting, diarrhea, and stomach pain. Some users may also experience headache, dizziness, or rash. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare professional.

Atovakon/Proguanil Glenmark should be used with caution in individuals with severe kidney disease or metabolic disorders. It is important to follow the prescribed dosage and complete the full course of treatment. This medication should be stored at room temperature and kept out of reach of children.

Atovakon/Proguanil Glenmark may interact with certain medications, including antacids, metoclopramide, and tetracycline antibiotics. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol should be avoided while using this medication.